Literature DB >> 25667436

Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis.

Beth Wallace1, Suzanne Kafaja2, Daniel E Furst2, Veronica J Berrocal3, Peter A Merkel4, James R Seibold5, Maureen D Mayes6, Dinesh Khanna7.   

Abstract

OBJECTIVE: Dyspnoea is a common, multifactorial source of functional impairment among patients with dcSSc. Our objective was to assess the reliability, construct validity and responsiveness to change of the Saint George's Respiratory Questionnaire (SGRQ) in patients with early dcSSc participating in a multicentre prospective study.
METHODS: At enrolment and 1 year, patients completed the SGRQ (a multi-item instrument with four scales: symptoms, activity, impact and total), a visual analogue scale (VAS) for breathing and the HAQ Disability Index (HAQ-DI) and underwent 6 min walk distance and pulmonary function tests, physician and patient global health assessments and high-resolution CT (HRCT). We assessed internal consistency reliability using Cronbach's α. For validity we examined the ability of the SGRQ to differentiate the presence vs absence of interstitial lung disease (ILD) on HRCT or restrictive lung disease and evaluated the 1 year responsiveness to change using pulmonary function tests and patient- and physician-reported anchors. Correlation coefficients of 0.24-0.36 were considered moderate and >0.37 was considered large.
RESULTS: A total of 177 patients were evaluated. Reliability was satisfactory for all SGRQ scales (0.70-0.93). All scales showed large correlations with the VAS for breathing and diffusing capacity of the lung for carbon monoxide in the overall cohort and in the subgroup with ILD. Three of the four scales in the overall cohort and the total scale in the ILD subgroup showed moderate to large correlation with the HAQ-DI and the predicted forced vital capacity (r = 0.33-0.44). Each scale discriminated between the presence and absence of ILD and restrictive lung disease (P ≤ 0.0001-0.03). At follow-up, all scales were responsive to change using different anchors.
CONCLUSION: The SGRQ has acceptable reliability, construct validity and responsiveness to change for use in a dcSSc population and differentiates between patients with and without ILD.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  autoinflammatory conditions; dyspnoea; patient attitude to health; patient-reported outcomes; quality of life; respiratory; scleroderma and related disorders; systemic sclerosis

Mesh:

Year:  2015        PMID: 25667436      PMCID: PMC4502336          DOI: 10.1093/rheumatology/keu456

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  46 in total

1.  Validation of the St. George's Respiratory Questionnaire in bronchiectasis.

Authors:  C B Wilson; P W Jones; C J O'Leary; P J Cole; R Wilson
Journal:  Am J Respir Crit Care Med       Date:  1997-08       Impact factor: 21.405

2.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

3.  High resolution computed tomography as a predictor of lung histology in systemic sclerosis.

Authors:  A U Wells; D M Hansell; B Corrin; N K Harrison; P Goldstraw; C M Black; R M du Bois
Journal:  Thorax       Date:  1992-09       Impact factor: 9.139

Review 4.  Systemic sclerosis: hypothesis-driven treatment strategies.

Authors:  Christina Charles; Philip Clements; Daniel E Furst
Journal:  Lancet       Date:  2006-05-20       Impact factor: 79.321

5.  Responsiveness to change: an aspect of validity, not a separate dimension.

Authors:  R D Hays; D Hadorn
Journal:  Qual Life Res       Date:  1992-02       Impact factor: 4.147

6.  Mortality in systemic sclerosis: an international meta-analysis of individual patient data.

Authors:  John P A Ioannidis; Panayiotis G Vlachoyiannopoulos; Anna-Bettina Haidich; Thomas A Medsger; Mary Lucas; Clement J Michet; Masataka Kuwana; Hidekata Yasuoka; Frank van den Hoogen; Liane Te Boome; Jacob M van Laar; Nicolette L Verbeet; Marco Matucci-Cerinic; Athanasios Georgountzos; Haralampos M Moutsopoulos
Journal:  Am J Med       Date:  2005-01       Impact factor: 4.965

7.  The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time.

Authors:  V D Steen; T A Medsger
Journal:  Arthritis Rheum       Date:  1997-11

8.  Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis.

Authors:  D Hanson; R H Winterbauer; S H Kirtland; R Wu
Journal:  Chest       Date:  1995-08       Impact factor: 9.410

9.  Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis.

Authors:  Alexandra B Wiese; Veronica J Berrocal; Daniel E Furst; James R Seibold; Peter A Merkel; Maureen D Mayes; Dinesh Khanna
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-11       Impact factor: 4.794

10.  Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials.

Authors:  Lesley Ann Saketkoo; Shikha Mittoo; Dörte Huscher; Dinesh Khanna; Paul F Dellaripa; Oliver Distler; Kevin R Flaherty; Sid Frankel; Chester V Oddis; Christopher P Denton; Aryeh Fischer; Otylia M Kowal-Bielecka; Daphne LeSage; Peter A Merkel; Kristine Phillips; David Pittrow; Jeffrey Swigris; Katerina Antoniou; Robert P Baughman; Flavia V Castelino; Romy B Christmann; Lisa Christopher-Stine; Harold R Collard; Vincent Cottin; Sonye Danoff; Kristin B Highland; Laura Hummers; Ami A Shah; Dong Soon Kim; David A Lynch; Frederick W Miller; Susanna M Proudman; Luca Richeldi; Jay H Ryu; Nora Sandorfi; Catherine Sarver; Athol U Wells; Vibeke Strand; Eric L Matteson; Kevin K Brown; James R Seibold
Journal:  Thorax       Date:  2013-12-24       Impact factor: 9.139

View more
  8 in total

Review 1.  Patient-reported outcome instruments in clinical trials of systemic sclerosis.

Authors:  John D Pauling; Joana Caetano; Corrado Campochiaro; Giacomo De Luca; Ana Maria Gheorghiu; Maria Grazia Lazzaroni; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2019-11-25

Review 2.  Assessment of disease outcome measures in systemic sclerosis.

Authors:  Robert Lafyatis; Eleanor Valenzi
Journal:  Nat Rev Rheumatol       Date:  2022-07-20       Impact factor: 32.286

3.  Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process.

Authors:  David Roofeh; Shaney L Barratt; Athol U Wells; Leticia Kawano-Dourado; Donald Tashkin; Vibeke Strand; James Seibold; Susanna Proudman; Kevin K Brown; Paul F Dellaripa; Tracy Doyle; Thomas Leonard; Eric L Matteson; Chester V Oddis; Joshua J Solomon; Jeffrey A Sparks; Robert Vassallo; Lara Maxwell; Dorcas Beaton; Robin Christensen; Whitney Townsend; Dinesh Khanna
Journal:  Semin Arthritis Rheum       Date:  2021-08-20       Impact factor: 5.431

4.  Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Authors:  Suzanne Kafaja; Philip J Clements; Holly Wilhalme; Chi-Hong Tseng; Daniel E Furst; Grace Hyun Kim; Jonathan Goldin; Elizabeth R Volkmann; Michael D Roth; Donald P Tashkin; Dinesh Khanna
Journal:  Am J Respir Crit Care Med       Date:  2017-11-03       Impact factor: 30.528

5.  Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II.

Authors:  Elizabeth R Volkmann; Donald P Tashkin; Holly LeClair; Michael D Roth; Grace Kim; Jonathan Goldin; Philip J Clements; Daniel E Furst; Dinesh Khanna
Journal:  ACR Open Rheumatol       Date:  2020-05-20

6.  A patient-centered approach to the burden of symptoms in patients with scleroderma treated with Bosentan: A prospective single-center observational study.

Authors:  Elena Rezus; Alexandra Maria Burlui; Bogdan Gafton; Teodora Alexa Stratulat; Gabriela Rusu Zota; Anca Cardoneanu; Ciprian Rezus
Journal:  Exp Ther Med       Date:  2019-12-20       Impact factor: 2.447

7.  Evaluation of health-related quality of life and the related factors in a group of Chinese patients with interstitial lung diseases.

Authors:  Xue-Yan Yuan; Hui Zhang; Li-Ru Huang; Fan Zhang; Xiao-Wen Sheng; Ai Cui
Journal:  PLoS One       Date:  2020-07-29       Impact factor: 3.240

8.  Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease.

Authors:  Tao Chen; Amy Po Yu Tsai; Seo Am Hur; Alyson W Wong; Mohsen Sadatsafavi; Jolene H Fisher; Kerri A Johannson; Deborah Assayag; Julie Morisset; Shane Shapera; Nasreen Khalil; Charlene D Fell; Helene Manganas; Gerard Cox; Teresa To; Andrea S Gershon; Nathan Hambly; Andrew J Halayko; Pearce G Wilcox; Martin Kolb; Christopher J Ryerson
Journal:  Respir Res       Date:  2021-07-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.